Combination Therapy (Tamsulosin + Finasteride)
Treatment for Benign Prostatic Hyperplasia
Typical Dosage: Tamsulosin 0.4mg daily + Finasteride 5mg daily
Effectiveness
75%
Safety Score
62%
Clinical Trials
7
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
62
DangerousModerateSafe
Treatment Details
Dosage Range
Tamsulosin 0.4mg daily + Finasteride 5mg daily
Time to Effect
2 weeks (initial) to 6 months (full effect)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$60
Monitoring:$250
Side Effect Mgmt:$175
Total Annual:$485
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$647
Comparison vs Tamsulosin Monotherapy
Cost Difference
+$130/year
More expensive
QALY Difference
+0.07 QALYs
Better outcomes
Dominance
No dominance
Combination Therapy (Tamsulosin + Finasteride) Outcomes
for Benign Prostatic Hyperplasia
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Common Side Effects
Dizziness
+18%
Abnormal ejaculation (retrograde)
+12%
Erectile dysfunction
+12%
Decreased libido
+6%
Orthostatic hypotension
+4%
Breast tenderness/enlargement
+1%
Active Clinical Trials
1 active trial recruiting for Combination Therapy (Tamsulosin + Finasteride) in Benign Prostatic Hyperplasia
Prostate Medication, Metabolism and Gut Microbiota
NCT06001619RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Turku, Finland +1 more
Started: Dec 1, 2022
Completed Clinical Trials
6 completed trials for Combination Therapy (Tamsulosin + Finasteride) in Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
NCT01435954COMPLETED
13.6K participants
OBSERVATIONAL
Started: Aug 1, 2010
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT01323998COMPLETED
35K participants
OBSERVATIONAL
Started: Apr 1, 2010
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
NCT01386983COMPLETED
332 participants
OBSERVATIONAL
Started: Mar 1, 2009
Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia
NCT07715448COMPLETEDPHASE4
240 participants
INTERVENTIONAL
Banī Suwayf, Egypt
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
NCT01390870COMPLETED
400 participants
OBSERVATIONAL
Started: May 1, 2009
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
NCT01332435COMPLETED
6.9K participants
OBSERVATIONAL
Started: Nov 1, 2009